AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2034244 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin and fluorouracil) followed by radiation therapy
Number of subjects: 332
Study 2034244 — intervention group
Group type: COMPARATOR
Intervention: Surgery followed by radiation therapy
Number of subjects: 332
Study 16435477 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for duodenal ulcer
Number of subjects: 91
Study 31351909 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer (GI) restorations
Number of subjects: 59
Study 31351909 — intervention group
Group type: COMPARATOR
Intervention: Composite resin (CR) restorations
Number of subjects: 59
Study 31351909 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GI and CR restorations
Number of subjects: 59
Study 30569748 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg inhaled terbutaline
Number of subjects: 16
Study 30569748 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg inhaled terbutaline
Number of subjects: 16
Study 30569748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28083705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 64
Study 28083705 — intervention group
Group type: COMPARATOR
Intervention: nasal Continuous Positive Airway Pressure (nCPAP)
Number of subjects: 64
Study 28083705 — intervention group
Group type: COMPARATOR
Intervention: Intraoral placebo appliance
Number of subjects: 64
Study 25993590 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX)
Number of subjects: 81
Study 25993590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 23666746 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein breakfast (60% of energy from protein)
Number of subjects: 8
Study 23666746 — intervention group
Group type: COMPARATOR
Intervention: High fat breakfast (60% of energy from fat)
Number of subjects: 8
Study 23666746 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate breakfast (60% of energy from carbohydrate)
Number of subjects: 8
Study 21148229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer computed tomography (CT) screening
Number of subjects: 1466
Study 21148229 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate baseline screening result
Number of subjects: 1466
Study 21148229 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1466
Study 21148229 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate result at the second screening round
Number of subjects: 1466
Study 19695904 — intervention group
Group type: EXPERIMENTAL
Intervention: Total percutaneous endovascular aneurysm repair with dual 6-F Perclose-AT preclosing technique
Number of subjects: 70
Study 19695904 — intervention group
Group type: COMPARATOR
Intervention: Surgical femoral cutdown
Number of subjects: 70
Study 17188099 — intervention group
Group type: COMPARATOR
Intervention: Computer-generated feedback about the economy of movements (Group A)
Number of subjects: 45
Study 17188099 — intervention group
Group type: COMPARATOR
Intervention: Computer-generated feedback with expert reference values (Group B)
Number of subjects: 45
Study 17188099 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal feedback from an expert (Group C)
Number of subjects: 45
Study 15189398 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted hysterectomy
Number of subjects: 1380
Study 15189398 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of abdominal and vaginal hysterectomy
Number of subjects: 1380
Study 11435810 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta power over frontal regions
Number of subjects: 39
Study 11435810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal volumes
Number of subjects: 39
Study 11435810 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 39
Study 11435810 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild cognitive impairment
Number of subjects: 39
Study 11435810 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild dementia
Number of subjects: 39
Study 9557848 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 89
Study 9557848 — intervention group
Group type: COMPARATOR
Intervention: Control (unhatched embryos)
Number of subjects: 89
Study 9443549 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1 mg/kg)
Number of subjects: 28
Study 9443549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2714503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel with intravenous oxytocin
Number of subjects: 91
Study 2714503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel with vaginal prostaglandin E2
Number of subjects: 91
Study 2714503 — intervention group
Group type: COMPARATOR
Intervention: Control group with intravenous oxytocin
Number of subjects: 91
Study 2714503 — intervention group
Group type: COMPARATOR
Intervention: Control group with vaginal prostaglandin E2
Number of subjects: 91
Study 1006474 — intervention group
Group type: EXPERIMENTAL
Intervention: meglumine ioglycamate
Number of subjects: 100
Study 31415206 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning using 'causes'
Number of subjects: 1360
Study 31415206 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning using 'may contribute to'
Number of subjects: 1360
Study 27491641 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 929
Study 27491641 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 929
Study 26248087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 16 weeks
Number of subjects: 592
Study 26248087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 24 weeks
Number of subjects: 592
Study 26248087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, peginterferon, and ribavirin for 12 weeks
Number of subjects: 592
Study 26248087 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 592
Study 23258579 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-oriented incentive spirometry (VIS)
Number of subjects: 20
Study 23258579 — intervention group
Group type: COMPARATOR
Intervention: Flow-oriented incentive spirometry (FIS)
Number of subjects: 20
Study 21863638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy de novo of adefovir dipivoxil (ADV) 10 mg per day and lamivudine (LMV) 100 mg per day
Number of subjects: 36
Study 21863638 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy of lamivudine (LMV) 100 mg per day
Number of subjects: 36
Study 21863638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy de novo of adefovir dipivoxil (ADV) and lamivudine (LMV)
Number of subjects: 36
Study 21863638 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy of lamivudine (LMV)
Number of subjects: 36
Study 21863638 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 19255394 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour adolescent medicine workshop using standardized patients (n = 95)
Number of subjects: 186
Study 19255394 — intervention group
Group type: COMPARATOR
Intervention: Alternative workshop (n = 91)
Number of subjects: 186
Study 16897291 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-soaked Surgicel in gallbladder bed
Number of subjects: 60
Study 16897291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltrated at trocar sites
Number of subjects: 60
Study 16897291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltrated into gallbladder bed and at trocar sites
Number of subjects: 60
Study 16897291 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in gallbladder bed and at trocar sites
Number of subjects: 60
Study 15054026 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment (attendance of a course involving theoretical and practical sessions)
Number of subjects: 0
Study 15054026 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (mailed information about BSE)
Number of subjects: 0
Study 15054026 — intervention group
Group type: EXPERIMENTAL
Intervention: New model for missing data
Number of subjects: 0
Study 15054026 — intervention group
Group type: EXPERIMENTAL
Intervention: MAR assumption
Number of subjects: 0
Study 11388817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (conjugated estrogens plus medroxyprogesterone)
Number of subjects: 2763
Study 11388817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study 9133887 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients
Number of subjects: 402
Study 9133887 — intervention group
Group type: COMPARATOR
Intervention: HIV negative patients
Number of subjects: 402
Study 8306923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 12 mg/d
Number of subjects: 159
Study 8306923 — intervention group
Group type: COMPARATOR
Intervention: Prazeapam 40 mg/d
Number of subjects: 159
Study 3731035 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cyclophosphamide (DOX/CTX)
Number of subjects: 52
Study 3731035 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus vinblastine (DOX/VBL)
Number of subjects: 52
Study 30584287 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal magnetic innervation (ExMI) therapy, 15 minutes, three times a week for 4 weeks
Number of subjects: 52
Study 30584287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic intervention)
Number of subjects: 52
Study 30584287 — intervention group
Group type: COMPARATOR
Intervention: Experimental group (ExMI therapy) vs Control group (no intervention)
Number of subjects: 52
Study 26448141 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 200 mg
Number of subjects: 82
Study 26448141 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 400 mg
Number of subjects: 82
Study 26448141 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg
Number of subjects: 82
Study 26448141 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 1200 mg
Number of subjects: 82
Study 26448141 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel (all doses)
Number of subjects: 82
Study 24352479 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment
Number of subjects: 80
Study 24352479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22344065 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching of the antagonist musculature
Number of subjects: 16
Study 22344065 — intervention group
Group type: COMPARATOR
Intervention: Nonstretch trial
Number of subjects: 16
Study 19279507 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) group (n = 16) participated in a supervised program 3 times per week.
Number of subjects: 24
Study 19279507 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group (n = 8) continued with standard of care.
Number of subjects: 24
Study 19279507 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) group (n = 16)
Number of subjects: 24
Study 19279507 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group (n = 8)
Number of subjects: 24
Study 17326152 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma1b 100 microg, 3 times a week for 48 weeks
Number of subjects: 502
Study 17326152 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma1b 200 microg, 3 times a week for 48 weeks
Number of subjects: 502
Study 17326152 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 times a week for 48 weeks
Number of subjects: 502
Study 15654136 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Intercourse (TI)
Number of subjects: 140
Study 15654136 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine Insemination (IUI)
Number of subjects: 140
Study 11453313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol
Number of subjects: 24
Study 11453313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9740347 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at 30% of maximum inspiratory mouth pressure for 30 min daily
Number of subjects: 18
Study 9740347 — intervention group
Group type: COMPARATOR
Intervention: Sham training at 15% of maximum inspiratory mouth pressure
Number of subjects: 18
Study 8092115 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of metoclopramide (regimen A)
Number of subjects: 54
Study 8092115 — intervention group
Group type: COMPARATOR
Intervention: Intermittent short infusion of metoclopramide (regimen B)
Number of subjects: 54
Study 2968223 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine eye drops (0.5%)
Number of subjects: 12
Study 2968223 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide (0.5%)
Number of subjects: 12
Study 2968223 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide (1.0%)
Number of subjects: 12
Study 6214996 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (500 mg every 12 h)
Number of subjects: 89
Study 6214996 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1 g every 12 h)
Number of subjects: 89
Study 6214996 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 89
Study 6214996 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 89
Study 30218227 — intervention group
Group type: EXPERIMENTAL
Intervention: FGG + LLLT (test group)
Number of subjects: 30
Study 30218227 — intervention group
Group type: COMPARATOR
Intervention: FGG + placebo LLLT (control group)
Number of subjects: 30
Study 27139726 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 5 µg ml-1
Number of subjects: 104
Study 27139726 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 100 µg ml-1
Number of subjects: 104
Study 25954317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger and artichoke supplementation
Number of subjects: 126
Study 25954317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 24622121 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a gene therapy
Number of subjects: 250
Study 24622121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 22935527 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy in non-CKD (n=4,747)
Number of subjects: 14706
Study 22935527 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy in mild CKD (n=2,135)
Number of subjects: 14706
Study 22935527 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy in severe CKD (n=229)
Number of subjects: 14706
Study 22935527 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy in HD (n=117)
Number of subjects: 14706
Study 19663622 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy (positive) messages (n = 68)
Number of subjects: 203
Study 19663622 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk (negative) messages (n = 67)
Number of subjects: 203
Study 19663622 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group (n = 68)
Number of subjects: 203
Study 17464561 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole, 20 mg bid with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid for 1 week, followed by placebo for 3 weeks
Number of subjects: 374
Study 17464561 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole, 20 mg bid with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid for 1 week, followed by omeprazole, 20 mg od for 3 weeks
Number of subjects: 374
Study 15247714 — intervention group
Group type: COMPARATOR
Intervention: Control (no anesthesia)
Number of subjects: 300
Study 15247714 — intervention group
Group type: EXPERIMENTAL
Intervention: PNB (periprostatic nerve block)
Number of subjects: 300
Study 15247714 — intervention group
Group type: EXPERIMENTAL
Intervention: PNB plus rectal lidocaine gel
Number of subjects: 300
Study 15247714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 300
Study 12566834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracystic chemotherapy with bleomycin (group A)
Number of subjects: 19
Study 12566834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracystic chemo‐radiotherapy with bleomycin and (32)P (group B)
Number of subjects: 19
Study 12566834 — intervention group
Group type: COMPARATOR
Intervention: Intracystic radiotherapy with (32)P and 0.9% saline (group C)
Number of subjects: 19
Study 9849419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) and Vindesine (V) with Cisplatin (P)
Number of subjects: 326
Study 9849419 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) and Vindesine (V) without Cisplatin (P)
Number of subjects: 326
Study 7974580 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty with transcranial Doppler monitoring
Number of subjects: 10
Study 7974580 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedure monitoring
Number of subjects: 10
Study 2605620 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPS Phenytoin
Number of subjects: 10
Study 2605620 — intervention group
Group type: COMPARATOR
Intervention: Epanutin
Number of subjects: 10
Study 2605620 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPS Phenytoin and Epanutin
Number of subjects: 10
Study 183462 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 28
Study 30488513 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting surgery plus medical therapy
Number of subjects: 0
Study 30488513 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study 28387949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 57
Study 28387949 — intervention group
Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 57
Study 28387949 — intervention group
Group type: COMPARATOR
Intervention: Resting exposure
Number of subjects: 57
Study 25931316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod 400 mg per os twice daily for the last 10 days of each month from October 2013 to April 2014
Number of subjects: 57
Study 25931316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 23819489 — intervention group
Group type: EXPERIMENTAL
Intervention: Degradable magnesium-based MgYREZr screws
Number of subjects: 26
Study 23819489 — intervention group
Group type: COMPARATOR
Intervention: Titanium screws
Number of subjects: 26
Study 21857015 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES 130/0.4)
Number of subjects: 115
Study 21857015 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 115
Study 19564809 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and intraurethral lidocaine
Number of subjects: 45
Study 19564809 — intervention group
Group type: COMPARATOR
Intervention: Topical lubricant control
Number of subjects: 45
Study 17584569 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 2022
Study 17584569 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2022
Study 15015186 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 900
Study 15015186 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 900
Study 15015186 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR with best medical treatment
Number of subjects: 900
Study 15015186 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 900
Study 11163386 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-unit all-porcelain crowns (SUAPC) preparation with acid etching
Number of subjects: 40
Study 9547840 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylator EM100
Number of subjects: 72
Study 9547840 — intervention group
Group type: COMPARATOR
Intervention: Bag ventilation
Number of subjects: 72
Study 7828353 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (0.2 IU/kg/week for 6 months)
Number of subjects: 19
Study 7828353 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (12 months)
Number of subjects: 19
Study 7828353 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro glucocorticoid sensitivity during GH therapy
Number of subjects: 19
Study 7828353 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm during open phase of GH therapy
Number of subjects: 19
Study 3277478 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.25 mg (group I, n = 11)
Number of subjects: 33
Study 3277478 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg (group II, n = 10)
Number of subjects: 33
Study 3277478 — intervention group
Group type: COMPARATOR
Intervention: Saline (group III, placebo group, n = 12)
Number of subjects: 33
Study 31314920 — intervention group
Group type: COMPARATOR
Intervention: Intralesional bleomycin (GA)
Number of subjects: 44
Study 31314920 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroporation and intralesional bleomycin (GB)
Number of subjects: 44
Study 27558785 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Impact of Vision Impairment (IVI) questionnaire
Number of subjects: 416
Study 24913915 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodex System 3 Pro
Number of subjects: 25
Study 24913915 — intervention group
Group type: COMPARATOR
Intervention: Cybex Humac Norm Model 770
Number of subjects: 25
Study 23168172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS) at birth
Number of subjects: 471
Study 21646051 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine treatment
Number of subjects: 47
Study 18374542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT)
Number of subjects: 120
Study 18374542 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Environmental Supports (GES)
Number of subjects: 120
Study 18374542 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 120
Study 17391577 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized communication system (SCS) providing detailed reports on ED visits.
Number of subjects: 2022